Verona Pharma Plc ADR (NASDAQ: VRNA) is 38.91% higher on its value in year-to-date trading and has touched a low of $11.39 and a high of $70.40 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VRNA stock was last observed hovering at around $64.18 in the last trading session, with the day’s gains setting it 0.33%.
Currently trading at $64.51, the stock is -1.53% and 4.49% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.93 million and changing 0.51% at the moment leaves the stock 68.67% off its SMA200. VRNA registered 310.63% gain for a year compared to 6-month gain of 117.50%. The firm has a 50-day simple moving average (SMA 50) of $61.7407 and a 200-day simple moving average (SMA200) of $38.246.
The stock witnessed a 1.56% loss in the last 1 month and extending the period to 3 months gives it a 42.47%, and is -2.66% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.69% over the week and 5.65% over the month.
Verona Pharma Plc ADR (VRNA) has around 209 employees, a market worth around $5.46B and $42.00M in sales. Fwd P/E is 126.49. Profit margin for the company is -413.39%. Distance from 52-week low is 466.37% and -8.37% from its 52-week high. The company has generated returns on investments over the last 12 months (-53.23%).
with sales reaching $41.47M over the same period.The EPS is expected to grow by 128.70% this year, but quarterly earnings will post 626.15% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
245.0 institutions hold shares in Verona Pharma Plc ADR (VRNA), with institutional investors hold 90.68% of the company’s shares. The shares outstanding are 84.63M, and float is at 74.21M with Short Float at 13.27%. Institutions hold 85.20% of the Float.
The top institutional shareholder in the company is FEDERATED HERMES, INC. with over 2.16 million shares valued at $31.29 million. The investor’s holdings represent 2.6806 of the VRNA Shares outstanding. As of 2024-06-30, the second largest holder is RA CAPITAL MANAGEMENT, L.P. with 7.63 million shares valued at $110.37 million to account for 1.1775 of the shares outstanding. The other top investors are PRICE T ROWE ASSOCIATES INC /MD/ which holds 0.95 million shares representing 1.1762 and valued at over $13.73 million, while NEA MANAGEMENT COMPANY, LLC holds 0.8616 of the shares totaling 5.58 million with a market value of $80.76 million.
Verona Pharma Plc ADR (VRNA) Insider Activity
The most recent transaction is an insider sale by Rickard Kathleen A., the company’s Chief Medical Officer. SEC filings show that Rickard Kathleen A. sold 79,264 shares of the company’s common stock on Mar 12 ’25 at a price of $8.35 per share for a total of $0.66 million. Following the sale, the insider now owns 2.61 million shares.
Still, SEC filings show that on Dec 05 ’24, ZACCARDELLI DAVID (President and CEO) disposed off 640,264 shares at an average price of $5.01 for $3.21 million. The insider now directly holds 14,367,552 shares of Verona Pharma Plc ADR (VRNA).
